{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:27:45Z","timestamp":1790872065079,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T00:00:00Z","timestamp":1758412800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    At the first interim analysis of the global, randomized, phase 3, double\u2010blind ADRIATIC trial in patients with limited\u2010stage small\u2010cell lung cancer (LS\u2010SCLC) not progressing after concurrent chemoradiotherapy (cCRT), consolidation durvalumab significantly improved overall survival (OS; hazard ratio [HR] 0.73) and progression\u2010free survival (PFS) by blinded independent central review (BICR; HR 0.76) versus placebo (dual primary endpoints). We report an exploratory analysis in patients enrolled in Japan. Patients received durvalumab 1500\u2009mg (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009264), durvalumab+tremelimumab 75 mg (4 doses,\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009200; arm remained blinded), or placebo (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u2009266) every 4\u2009weeks for \u2264\u200924 months. Prior cCRT \u00b1 prophylactic cranial irradiation (PCI) was per local standards of care. In the Japan subgroup, 19 and 31 patients received durvalumab and placebo, respectively; prior cCRT comprised cisplatin\u2010etoposide\/carboplatin\u2010etoposide in 94.7\/5.3% and 87.1\/12.9% and once\u2010daily\/twice\u2010daily radiotherapy in 10.5\/89.5% and 0\/100%; 52.6% and 58.1% received PCI. Median OS was not reached versus 44.9 months (3\u2010year OS 67.4% versus 58.1%; HR 0.67, 95% CI 0.24\u20131.62). Median PFS by BICR was 44.2 versus 29.4 months (24\u2010month PFS 59.6% vs. 58.6%; HR 1.05, 95% CI 0.44\u20132.36); median PFS by investigator assessment (sensitivity analysis) was 44.2 versus 19.7\u2009months (24\u2010month PFS 65.6% vs. 47.0%; HR 0.68, 95% CI 0.28\u20131.51). With durvalumab and placebo, 21.1% and 19.4% had maximum grade 3\u20134 adverse events (AEs), 21.1% and 9.7% had AEs leading to treatment discontinuation, and 52.6% and 45.2% had pneumonitis\/radiation pneumonitis (grade 3\u20134: 0% and 6.5%). In conclusion, consolidation durvalumab demonstrated a favorable risk\/benefit profile in Japanese patients with LS\u2010SCLC post cCRT.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Trial Registration:<\/jats:bold>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    identifier: NCT03703297.\n                  <\/jats:p>","DOI":"10.1111\/cas.70188","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T02:24:17Z","timestamp":1758507857000},"page":"3171-3184","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited\u2010Stage Small\u2010Cell Lung Cancer in the Phase 3\n                    <scp>ADRIATIC<\/scp>\n                    Trial"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-9065","authenticated-orcid":false,"given":"Yoshitaka","family":"Zenke","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology National Cancer Center Hospital East  Kashiwa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Goto","sequence":"additional","affiliation":[{"name":"Research and Development National Cancer Center Hospital  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Kurume University School of Medicine  Kurume Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Okishio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology National Hospital Organization Kinki Chuo Chest Medical Center  Sakai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Ogino","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine &amp; Rheumatology Tokushima University Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology Aichi Cancer Center Hospital  Nagoya Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Oizumi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine National Hospital Organization Hokkaido Cancer Center  Sapporo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Hayama","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nii","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Harada","sequence":"additional","affiliation":[{"name":"AstraZeneca K.K.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mann","sequence":"additional","affiliation":[{"name":"AstraZeneca  Cambridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka S.","family":"Olivo","sequence":"additional","affiliation":[{"name":"AstraZeneca  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyi","family":"Jiang","sequence":"additional","affiliation":[{"name":"AstraZeneca  Gaithersburg Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Senan","sequence":"additional","affiliation":[{"name":"Amsterdam University Medical Centers Vrije Universiteit Amsterdam, Cancer Center Amsterdam  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_12_3_1","volume-title":"Part 1: Lung Cancer Clinical Practice Guidelines, Localized Small Cell Lung Cancer (LD\u2010SCLC)","author":"Japan Lung Cancer Society","year":"2024"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33962"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20180112"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.071"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094\u2010023\u201003216\u20103"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.7918"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03364"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29098"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.11.014"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326\u20106066.CIR\u201014\u20100191"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx670"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147\u2010021\u201001899\u20108"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.12.25"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15816"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13932"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2019.07.005"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637\u2010016\u20100347\u20106"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad195"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14003"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201023\u20102568"},{"key":"e_1_2_12_28_1","volume-title":"AJCC Cancer Staging Manual","author":"Amin M. B.","year":"2017"},{"key":"e_1_2_12_29_1","volume-title":"North Fort Myers","author":"Rami\u2010Porta R.","year":"2016"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.11.020"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)32222\u20106"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100686"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2324"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30318\u20102"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2022.01.032"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.02.063"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen\u20102016\u2010000119"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2019.08.29"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100638"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.12.150"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102246"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.70188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T10:40:15Z","timestamp":1762425615000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.70188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,21]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/cas.70188"],"URL":"https:\/\/doi.org\/10.1111\/cas.70188","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,21]]},"assertion":[{"value":"2025-06-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}